title: High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
abstract: The optimum treatment of primary CNS lymphoma (PCNSL) is not yet determined. The objective of this study was to assess the safety and efficacy of initial methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) in patients with newly diagnosed PCNSL. Twenty-five patients received two courses of initial chemotherapy combining methotrexate, etoposide, carmustine and methylprednisolone, and one course of ifosfamide-cytarabine followed by peripheral stem cell collection. Seventeen responsive patients then received HDT using carmustine, etoposide, cytarabine and melphalan with autologous stem cell rescue. After ASCT for responding patients or after salvage therapy for non-responders, whole brain radiation therapy at a dose of 30 Gy was delivered. The objective response rate to the induction chemotherapy was 84%. Four of the 21 responding patients did not have ASCT because of toxicity or refusal. With a median follow-up time of 34 months, the projected event free survival rate is 46% at 4 years. Projected overall survival is 64% at 4 years. Sixteen patients are actually in continuous complete response. No evidence of late treatment-related toxicity was observed. This treatment approach appears feasible in newly diagnosed PCNSL with encouraging results.
authors.affiliation: Hématologie, CHU Tours, Cedex, France. colombat@med.univ-tours.fr
authors.forename: Ph
authors.initials: P
authors.lastname: Colombat
authors.forename: A
authors.initials: A
authors.lastname: Lemevel
authors.forename: P
authors.initials: P
authors.lastname: Bertrand
authors.forename: V
authors.initials: V
authors.lastname: Delwail
authors.forename: P
authors.initials: P
authors.lastname: Rachieru
authors.forename: A
authors.initials: A
authors.lastname: Brion
authors.forename: C
authors.initials: C
authors.lastname: Berthou
authors.forename: J O
authors.initials: JO
authors.lastname: Bay
authors.forename: R
authors.initials: R
authors.lastname: Delepine
authors.forename: B
authors.initials: B
authors.lastname: Desablens
authors.forename: S
authors.initials: S
authors.lastname: Camilleri-Broët
authors.forename: C
authors.initials: C
authors.lastname: Linassier
authors.forename: T
authors.initials: T
authors.lastname: Lamy
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002330:Carmustine / Q000008:administration & dosage; D016543:Central Nervous System Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D012074:Remission Induction; D033581:Stem Cell Transplantation / Q000401:mortality; D014182:Transplantation, Autologous
chemical_list: D003561:Cytarabine; D005047:Etoposide; D002330:Carmustine; D007069:Ifosfamide; D008775:Methylprednisolone; D008727:Methotrexate